

# Torben Plesner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3516111/publications.pdf>

Version: 2024-02-01

66  
papers

5,852  
citations

201658

27  
h-index

123420

61  
g-index

67  
all docs

67  
docs citations

67  
times ranked

4741  
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 1319-1331.	27.0	1,210
2	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 1207-1219.	27.0	948
3	Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. <i>Blood</i> , 2016, 128, 384-394.	1.4	697
4	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2104-2115.	27.0	684
5	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. <i>Blood</i> , 2016, 128, 37-44.	1.4	347
6	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , 2016, 127, 681-695.	1.4	179
7	Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. <i>Blood Advances</i> , 2017, 1, 2105-2114.	5.2	155
8	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1582-1596.	10.7	141
9	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. <i>Clinical Cancer Research</i> , 2017, 23, 7498-7511.	7.0	134
10	High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 279-289.	1.5	117
11	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , 2016, 128, 1821-1828.	1.4	98
12	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. <i>Blood</i> , 2019, 134, 668-677.	1.4	87
13	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. <i>Lancet Haematology</i> , the, 2020, 7, e447-e455.	4.6	74
14	Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. <i>Leukemia</i> , 2021, 35, 573-584.	7.2	67
15	Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 2 study. <i>Lancet Haematology</i> , the, 2020, 7, e395-e407.	4.6	65
16	Daratumumab for the Treatment of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 1228.	4.8	59
17	Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. <i>Journal of Clinical Oncology</i> , 2021, 39, 1139-1149.	1.6	57
18	Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). <i>Journal of Clinical Oncology</i> , 2021, 39, 3602-3612.	1.6	44

#	ARTICLE	IF	CITATIONS
19	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.	1.4	43
20	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. <i>Leukemia</i> , 2022, 36, 1066-1077.	7.2	39
21	Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX). <i>Blood</i> , 2016, 128, 4531-4531.	1.4	36
22	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , 2016, 76, 853-867.	10.9	34
23	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	2.7	33
24	Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). <i>Blood</i> , 2018, 132, LBA-2-LBA-2.	1.4	30
25	Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study. <i>Blood</i> , 2020, 136, 24-26.	1.4	29
26	Prophylactic immunoglobulin therapy in secondary immune deficiency – an expert opinion. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 921-926.	3.0	28
27	Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone. <i>Blood</i> , 2016, 128, 246-246.	1.4	28
28	Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. <i>Blood</i> , 2019, 134, 1875-1875.	1.4	26
29	Monoclonal antibodies in myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 599-609.	0.3	26
30	Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). <i>Haematologica</i> , 2021, 106, 1725-1732.	3.5	25
31	Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray, low-dose computed tomography, and 18fluorodeoxyglucose positron emission tomography in previously untreated patients. <i>Haematologica</i> , 2016, 101, e415-e418.	3.5	24
32	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , 2018, 57, 529-538.	3.5	24
33	Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 227-237.	1.6	22
34	Immunochemical Studies of Human $\kappa$ 2-Microglobulin.. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1980, 35, 627-637.	5.7	21
35	Subcellular Distribution of Urokinase and Urokinase Receptor in Human Neutrophils Determined by Immunoelectron Microscopy. <i>Ultrastructural Pathology</i> , 2000, 24, 175-182.	0.9	19
36	Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study. <i>Blood</i> , 2017, 130, 838-838.	1.4	19

#	ARTICLE	IF	CITATIONS
37	Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor. <i>Blood</i> , 2018, 132, 3272-3272.	1.4	17
38	Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?. <i>Cells</i> , 2020, 9, 378.	4.1	16
39	Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8590-8590.	1.6	16
40	Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment. <i>Haematologica</i> , 2016, 101, e419-e422.	3.5	14
41	Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report. <i>Haematologica</i> , 2019, 104, e432-e433.	3.5	13
42	Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. <i>British Journal of Haematology</i> , 2021, 194, 132-139.	2.5	13
43	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma ( GEN 503): final results of an open-label, phase 1/2 study. <i>British Journal of Haematology</i> , 2019, 186, e35-e39.	2.5	12
44	Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study Oâ€12â€M1. <i>British Journal of Haematology</i> , 2021, 193, 1105-1109.	2.5	11
45	Clinically-suspected cast nephropathy: A retrospective, national, real-world study. <i>American Journal of Hematology</i> , 2020, 95, 1352-1360.	4.1	9
46	Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma. <i>Blood</i> , 2015, 126, 3037-3037.	1.4	9
47	Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO). <i>Blood</i> , 2018, 132, 2006-2006.	1.4	8
48	High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action. <i>Blood</i> , 2016, 128, 4521-4521.	1.4	8
49	Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8016-8016.	1.6	7
50	Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8013-8013.	1.6	6
51	Facilitated subcutaneous immunoglobulin administration (fSClg): a new treatment option for patients with secondary immune deficiencies. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 705-711.	3.0	5
52	Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8025-8025.	1.6	4
53	Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8035-8035.	1.6	4
54	High-dose therapy improves the bone remodelling compartment canopy coverage and bone formation in multiple myeloma. <i>British Journal of Haematology</i> , 2015, 171, 355-365.	2.5	3

#	ARTICLE	IF	CITATIONS
55	Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry. <i>Blood</i> , 2019, 134, 1849-1849.	1.4	2
56	Corticosteroid tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 8537-8537.	1.6	1
57	Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO). <i>Blood</i> , 2018, 132, 1995-1995.	1.4	1
58	Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study. <i>Blood</i> , 2021, 138, 1667-1667.	1.4	1
59	Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose. <i>Blood</i> , 2021, 138, 1646-1646.	1.4	1
60	Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study. <i>Journal of Clinical Oncology</i> , 2022, 40, 8044-8044.	1.6	1
61	â€œFine-tuning cytoreduction in resistant multiple myeloma â€” progress here, tooâ€?. <i>British Journal of Haematology</i> , 2019, 187, 275-276.	2.5	0
62	Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab. <i>Journal of Clinical Medicine</i> , 2021, 10, 1002.	2.4	0
63	Long-Lasting Remissions for Myeloma Patients on Daratumumab Therapy from the GEN501 and GEN503 Trials. <i>Blood</i> , 2018, 132, 3308-3308.	1.4	0
64	Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study. <i>Blood</i> , 2019, 134, 5553-5553.	1.4	0
65	Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma. <i>Clinical Hematology International</i> , 2020, 2, 35.	1.7	0
66	Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA. <i>Blood</i> , 2021, 138, 4095-4095.	1.4	0